Astena Holdings Co.,Ltd.
TTSE:8095523.00
JPY
+2.00
(+0.38%)
ISIN
JP3150000002
Return %
Stock
S&P 500
1Y
8.06
14.20
3Y
-0.95
81.12
5Y
-5.60
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Satoshi Setoguchi
- Full Time Employees
- 1,543
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 4-8-2 Nihonbashihoncho Tokyo TY Japan 103-8403
- IPO Date
- Jul 2, 1963
- Website
- astena-hd.com
- Similar Companies
- Business
- Astena Holdings Co., Ltd. Astena Holdings Co., Ltd. (TSE:8095) serves as the holding company for the Astena Group, a diversified Japanese enterprise operating across five core segments: Fine Chemicals; Health & Beauty Care, Food; Medical; Industrial Chemicals; and Social Impact Business; headquartered in Tokyo with additional facilities in Suzu, Ishikawa Prefecture; founded in 1914 as a pharmaceutical wholesaler and established in its current form in 1941. In the Fine Chemicals segment, the group provides comprehensive services encompassing chemistry, manufacturing, and controls (CMC) research and development, contract development and manufacturing organization (CDMO) for solid and injectable formulations compliant with PIC/S GMP standards in Japan, the US, and Europe, procurement of active pharmaceutical ingredients (APIs), intermediates, and additives from domestic and overseas manufacturers, and production of generic drug substances via subsidiaries such as SPERA PHARMA, Inc., SPERA NEXUS, Inc., Jitsubo CO., LTD., and IWAKI SEIYAKU SAKURA FACTORY CO., LTD. The Health & Beauty Care, Food segment supplies cosmetic raw materials including 1,3-butylene glycol, natural plant extracts, sodium acetylated hyaluronate, and tea-tree oil; food ingredients such as yeast extracts, dehydrated vegetables, tomato powder, meat extracts, and functional foods like black vinegar dehydrated extract; alongside consumer products via e-commerce and retail through in-house brands from IWAKI & CO., LTD., APROS Co., Ltd. (cellfuture skincare and makeup), Maruman H&B Co., Ltd. (Pureal cosmetics, placenta, propolis health foods), AINS-LAB INC. (import agency and analysis services), and equity-method affiliate Bohen-Kasei Co., Ltd.; while the Life Science unit supports drug discovery with research reagents and medical devices. The Medical segment develops, manufactures, and sells pharmaceuticals focused on topical semi-solid formulations (ointments, creams, lotions) with top domestic market share in steroid-based (10 ingredients, 25 products) and antifungal (6 ingredients, 12 products) categories, solid formulations including tablets and powders, and Navision DR medical institution-exclusive cosmetics, primarily through IWAKI SEIYAKU CO., LTD. with nationwide medical representatives; the Industrial Chemicals segment delivers surface treatment chemicals for printed circuit boards (via-fill plating, seed-layer etchants), electronic components (tin plating for MLCC), semiconductors (sensors, power modules), and automotive applications, plus related equipment, metal salts, and consumables via Meltex Inc., Tokai Meltex Inc., Tokyo Kakoki Co., Ltd., and overseas subsidiaries in Hong Kong, China, Taiwan, South Korea, and Thailand. The Social Impact Business segment pursues regional co-creation in primary industries, energy, tourism, human resources, and education through Astena Minerva Inc., Ishikawa Zukan Co., Ltd., AM Trading Co., Ltd., PIXTURE Co., Ltd., Oku Noto SDGs Investment Limited Partnership, and TUAT No. 1 Investment Limited Partnership, emphasizing ESG-driven sustainable growth in areas like Suzu-shi. Recent developments include the 2021 transition to a holding company structure with renaming from Iwaki & Co., Ltd., relocation of select head office functions to Suzu-shi, Ishikawa Prefecture, full acquisition of subsidiaries like SPERA PHARMA Inc., IWAKI SEIYAKU SAKURA FACTORY CO., LTD., Maruman H&B Co., Ltd., Jitsubo CO., LTD., and AINS-LAB INC., establishment of Astena Heartful Co., Ltd. and PIXTURE Co., Ltd., listing upgrade to Tokyo Stock Exchange Prime Section in 2022, leadership change to Satoshi Setoguchi as president in 2024 marking the 110th anniversary, and commissioning of a new injectable formulation production line in November 2023 at the Pharmaceutical Contract Manufacturing BU for investigational and commercial drugs across Japan, the US, and Europe.